Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

77.31USD
14 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$77.31
Open
$77.11
Day's High
$77.82
Day's Low
$77.11
Volume
4,400,233
Avg. Vol
6,855,992
52-wk High
$89.54
52-wk Low
$64.27

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $99,769.02
Shares Outstanding(Mil.): 1,300.26
Dividend: 0.57
Yield (%): 2.95

Financials

  GILD.O Industry Sector
P/E (TTM): 13.19 169.61 31.56
EPS (TTM): 5.85 -- --
ROI: 14.59 1.42 12.88
ROE: 34.68 0.52 15.04

Gilead CEO Milligan, Chairman Martin to step down

Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men.

Jul 25 2018

UPDATE 4-Gilead CEO Milligan, Chairman Martin to step down

July 25 Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men.

Jul 25 2018

Gilead CEO Milligan, Chairman Martin to step down

July 25 Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan will step down at the end of the year and that Chairman John Martin will follow soon after, but the biotech did not announce a successor for either man.

Jul 25 2018

GSK's two-drug HIV treatment proves itself in key tests

LONDON GlaxoSmithKline's simple two-drug treatment for HIV works as well as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, clinical study results presented on Tuesday showed.

Jul 24 2018

GSK's two-drug HIV treatment proves itself in key tests

LONDON, July 24 GlaxoSmithKline's simple two-drug treatment for HIV works as well as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, clinical study results presented on Tuesday showed.

Jul 24 2018

CORRECTED-UPDATE 1-Rival Novartis, Gilead CAR-T therapies win European panel recommendation

ZURICH, June 29 Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within months.

Jun 29 2018

Rival Novartis, Gilead CAR-T therapies win European panel recommendation

June 29 - Rival cancer cell therapies from Swiss drugmaker Novartis and U.S.-based Gilead Sciences won a key recommendation from a European Medicines Agency panel, likely clearing their way for approval within a couple of months.

Jun 29 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON, June 20 GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

Jun 20 2018

UPDATE 2-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

Jun 14 2018

BRIEF-FDA Approves Expanded Indication For Truvada

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION FOR TRUVADA® (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) FOR REDUCING THE RISK OF ACQUIRING HIV-1 IN ADOLESCENTS

May 15 2018

Earnings vs. Estimates